The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): A small pilot study

The Spectrum of Inflammatory Myopathies: Dermatomyositis, Polymyositis, Necrotizing Myositis, and Inclusion-Body Myositis

“…Alemtuzumab may provide short-term stabilization [ 74 ] but a controlled study is needed. Anti-ILI receptor (Anakinra) failed [ 75 ]. Trials targeting muscle-inhibiting TGF-b molecules or muscle growth factors are in progress.…”

Inflammatory Muscle Diseases

“…Treatment with anakinra has also not been successful. 77 Trials targeting muscle-inhibiting TGF-β molecules or muscle growth factors are in progress. Bimagrumab, an antibody that inhibits the signaling of a TGF-β superfamily receptor, was shown in a small-scale study to increase muscle volume after 8 weeks, 78 which has prompted an ongoing controlled study (ClinicalTrials.gov number, NCT01925209).…”

Immunotherapies for Immune-Mediated Myopathies: A Current Perspective

“…A small open trial of the TNF-α blocker etanercept in a group of 9 patients with IBM treated for an average of 17 months showed a small but significant improvement in hand grip strength at 12 months compared with a natural history cohort of patients and may warrant further evaluation in a controlled trial [136]. A small pilot study of the IL-1 receptor antagonist anakinra administered to 4 patients with longstanding IBM for a mean period of 7.7 months did not demonstrate any improvement in muscle strength or disease stabilization [137]. However, as in the case of IVIG it is possible that these cytokine-based therapies may be more effective if they are given at an earlier stage of the disease and over a longer timeframe.…”